# A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

> **NCT00246987** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 341 (—)

## Conditions studied

- Diabetes, Type 2

## Interventions

- **DRUG:** Muraglitazar

## Key facts

- **NCT ID:** NCT00246987
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 341 (—)
- **Last updated:** 2012-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246987, "A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00246987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*